ОСОБЕННОСТИ ЛЕЧЕНИЯ COVID-19 У ПАЦИЕНТОВ С КОМОРБИДНЫМИ ЗАБОЛЕВАНИЯМИ: ВЛИЯНИЕ НА ЛЕГКИЕ И ПОЧКИ (ОБЗОР ЛИТЕРАТУРЫ)
Ключевые слова:
COVID-19, коморбидности, острая почечная недостаточность, ОРДСАннотация
Пандемия COVID-19 оказала значительное влияние на мировую систему здравоохранения, особенно на людей с предшествующими заболеваниями. Этот обзор исследует взаимосвязь между коморбидностями и прогрессированием COVID-19, с акцентом на вовлечение почек и легких. Острая почечная недостаточность (ОПН) и острый респираторный дистресс-синдром (ОРДС) являются критическими осложнениями, особенно у пациентов с хронической болезнью почек (ХБП). В обзоре освещены современные терапевтические подходы, включая заместительную почечную терапию (ЗПТ) и непрерывную заместительную почечную терапию (НЗПТ), которые показали улучшение результатов в тяжелых случаях. Необходимы дальнейшие исследования для улучшения стратегий лечения и улучшения исходов пациентов.
Библиографические ссылки
Index.minfin. Official data of the Ministry of Finance of the Republic of Uzbekistan, 2023. Available at: https://index.minfin.com.ua/reference/coronavirus/geography/uzbekistan/
Oyelade T., Alqahtani J., Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: An early systematic review and meta-analysis. Trop Med Infect Dis. 2020;5(2):80. doi:10.3390/tropicalmed5020080.
Guan W-J, Ni Z-Y, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720. doi:10.1056/NEJMoa2002032.
Hu L., Chen S., Fu Y., et al. Risk factors associated with clinical outcomes in 323 COVID-19 patients in Wuhan, China. Journal of Clinical Virology. 2020;127:104371. doi:10.1016/j.jcv.2020.104371.
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343-346. doi:10.15585/mmwr.mm6912e2.
Cummings M.J., Baldwin M.R., et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020;395(10239):1763–1770. doi:10.1016/S0140-6736(20)31189-2.
Braun F., Lütgehetmann M., Pfefferle S., et al. SARS-CoV-2 renal tropism associates with acute kidney injury. The Lancet. 2020;396(10251):597-598. doi:10.1016/S0140-6736(20)31759-1.
Ye G., Pan Z., Pan Y., et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. Journal of Infectious Diseases. 2020;80(5). doi:10.1016/j.jinf.2020.03.001.
Van Elslande J., Vermeersch P., Vandervoort K., et al. Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain. Clinical Infectious Diseases. 2020; ciaa1330. doi:10.1093/cid/ciaa1330.
Nicholson E., Avadhanula V., Fragoso S., et al. SARS-CoV-2 re-infection versus prolonged shedding: A case series. Preprint. Available at: https://d197for5662m48.cloudfront.net/documents/publicationstatus/63133/preprint_pdf/4208b09a79ce5737322389d0124f4c55.pdf.
To K.K., Hung I.F., Ip J.D., et al. Coronavirus disease 2019 (COVID-19) re-infection by a phylogenetically distinct severe acute respiratory syndrome coronavirus 2 strain confirmed by whole genome sequencing. Clinical Infectious Diseases. 2021;73(9). doi:10.1093/cid/ciaa1275.
Remuzzi A., Remuzzi G. COVID-19 and Italy: what next? The Lancet. 2020;395(10231):1225–1228. doi:10.1016/S0140-6736(20)30627-9.
Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648.
Pei G., Zhang Z., Peng J., et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. Journal of the American Society of Nephrology. 2020;31(6):1157–1165. doi:10.1681/ASN.2020030276.
Wang X., Fang X., Cai Z., et al. Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: A systemic review and meta-analysis. Research. 2020;2020:2402961. doi:10.34133/2020/2402961.
Taverna G., Di Francesco S., Borroni E., et al. The kidney, COVID-19, and the chemokine network: an intriguing trio. International Urology and Nephrology. 2021;53:97–104. doi:10.1007/s11255-020-02579-8.
Nasiri M.J., Haddadi S., Tahvildari A., et al. COVID-19 clinical characteristics and sex-specific risk of mortality: systematic review and meta-analysis. Frontiers in Medicine. 2020;7:459. doi:10.3389/fmed.2020.00459.
Guan W.J., Liang W.H., Zhao Y., et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: A nationwide analysis. European Respiratory Journal. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020.
Rubin S., Orieux A., Prevel R., et al. Characterisation of acute kidney injury in critically ill patients with severe coronavirus disease-2019 (COVID-19). medRxiv. 2020; doi:10.1101/2020.05.06.20069872.
Sabaghian T., Kharazmi A.B., Ansari A., et al. COVID-19 and acute kidney injury: A systematic review and meta-analysis. Frontiers in Medicine. 2022;9:705908. doi:10.3389/fmed.2022.705908.
Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney International. 2020;98:209-218. doi:10.1016/j.kint.2020.05.006.
Perico L., Benigni A., Remuzzi G. Should COVID-19 concern nephrologists? Why and to what extent? Nephron. 2020;144(5):213-221. doi:10.1159/000507305.
WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023.
Budhathoki P., Shrestha D.B., Rawal E., Khadka S. Corticosteroids in COVID-19: Is it rational? A systematic review and meta-analysis. SN Comprehensive Clinical Medicine. 2020;1-21. doi:10.1007/s42399-020-00515-6.
Naicker S., Yang C.W., Hwang S.J., et al. The novel coronavirus 2019 epidemic and kidneys. Kidney International. 2020;97(5):829–838. doi:10.1016/j.kint.2020.03.005.
Naicker S., Forni L.G., Mehta R.L., et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nature Reviews Nephrology. 2020;16(12):747-764. doi:10.1038/s41581-020-00356-5.
Sathyakamala R., Peace A.R., Shanmugam P., et al. A comparative study on bacterial co-infections and prevalence of multidrug resistant organisms among patients in COVID and non-COVID Intensive Care Units. Journal of Preventive Medicine and Hygiene. 2022;63(1). doi:10.15167/2421-4248/jpmh2022.63.1.2175.
Mutua J.M., Mwaniki N.J., Musyoki A.M. Multidrug resistant bacterial infections in severely ill COVID-19 patients admitted in a national referral and teaching hospital, Kenya. BMC Infectious Diseases. 2022;22:877. doi:10.1186/s12879-022-07885-3.
Fowler R.A., Lapinsky S.E., Hallett D., et al. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290(3):367-373. doi:10.1001/jama.290.3.367.
Liakopoulos V., Roumeliotis S., Papachristou S., et al. COVID-19 and acute kidney injury: A pathophysiological overview. Kidney International. 2022;98:1296-1307. doi:10.1016/j.kint.2020.07.019.
Zhang H., Penninger J.M., Li Y., et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target. Intensive Care Medicine. 2020;46(4):586–590. doi:10.1007/s00134-020-05985-9.
Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. The Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3.
Zhang Z., Zhang L., Zha D., et al. COVID-19 and the kidney: A systematic review. The Lancet. 2020; doi:10.1016/S0140-6736(20)30566-3.
Chen Y.T., Shao S.C., Hsu C.K., et al. Incidence of acute kidney injury in COVID-19 infection: A systematic review and meta-analysis. Critical Care. 2020;24:346. doi:10.1186/s13054-020-03009-y.
WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim Guidance. 2020. Available at: https://www.who.int/publications/i/item/clinical-management-of-covid-19
Hirsch J.S., Ng J.H., Ross D.W., et al. Acute kidney injury in patients hospitalized with COVID-19 in New York City. Kidney International Reports. 2020; doi:10.1016/j.kint.2020.05.006.
Sterne J.A.C., Murthy S., Diaz J.V., et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330–1341. doi:10.1001/jama.2020.17023.
Budhathoki P., Shrestha D.B., Rawal E., et al. Risk of death associated with corticosteroid use in COVID-19 patients: A meta-analysis. Journal of Clinical Medicine. 2020;9(5):1733. doi:10.3390/jcm9051733.
Ghani R.A., Zainudin S., Kong N.T., et al. Serum IL-6 and IL-1ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. Nephrology Dialysis Transplantation. 2006;11:386-393. doi:10.1111/j.1440-1797.2006.00600.x.
